Dr Daniel Chan
MBBS (Honours) 2000 –National University of Singapore School of Medicine, MRCP (UK) 2004 –Royal College of Physicians United Kingdom, FAMS (Medical Oncology) 2009 –Academy of Medicine Singapore, FRCP (Edinburgh) 2015 – Royal College of Physicians Edinburgh
Dr Chan graduated with distinction of honours from National University of Singapore (NUS) School of Medicine. He was further trained in internal medicine and obtained the MRCP (UK) in 2004. He received his medical oncology specialist training with the National University Cancer Institute of Singapore. He finished his final year of fellowship in the USA at the University of California, Los Angeles (UCLA) and Cedars-Sinai Medical Centre. Dr Chan furthered his medical oncology clinical experience at UCLA and Cedars-Sinai with Dr Ronald Natale (lung cancer), Dr Michael Lill (lymphoma), Dr Charles Forscher (sarcoma) and Dr Albert Lai (neuro-oncology) under an endowment grant from the National University Hospital of Singapore. He also pursued research in the laboratory of haematologist-oncologist Professor Phillip Koeffler as part of a National Medical Research Council Overseas Fellowship.
Upon his return, Dr Chan was a specialist in medical oncology at the National University Cancer Institute Singapore and director of undergraduate education (medical oncology) at the National University of Singapore. He was also actively involved in cancer research at the Cancer Science Institute Singapore. Dr Chan is a member of the American Society of Clinical Oncology, and in 2015 he was elected to be a fellow in the Royal College of Physicians, Edinburgh.
Achievements and Accolades
- Published in international peer reviewed journals including Proceedings of the National Academy of Sciences (USA), Annals of Oncology and Investigational New Drugs on breast cancer, melanoma, thyroid cancer, nasopharyngeal cancer and myeloproliferative neoplasms.
- Written a book chapter on breast cancer in “Oncogene and Cancer – From Bench to Clinic“
- Was involved as a co-investigator in trials of new oncology drugs and held a national research grant in triple-negative breast cancer in NCIS
- Awarded the Excellent Service Award (EXSA) and STAR award (from SPRING Singapore) on multiple occasions for exemplary service to his patients
- First in South Asia to use the PD-1 immunotherapy drug (Pembrolizumab) in clinical practice
Sub specialty interests: Breast, lung and colon cancers, lymphoma, neuro-oncology and sarcoma